Imcyse to initiate Phase Ib trial of Imotopes to treat type 1 diabetes

Immunotherapeutic vaccines developer Imcyse is set to initiate the Phase Ib clinical trial of Imotopes for the treatment of insulin-dependent (type 1) diabetes, following the authorisation from the regulatory authorities of Belgium and the UK.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news